Please Wait a Moment
X

CTS History

01Dec

Babesia

SuperUser Account |01 Dec, 2015 | Return|

In October, due to demand from existing healthcare partners, CTS began testing blood donors for antibody to Babesia microti under an Investigational New Drug exemption as a release test.

About the Author

Related

CTS Founded

CTS Founded

In January, CTS is incorporated as a non-profit organization owned by Vitalant and OneBlood (formerl...

Read More >
Implementation of a COVID-19 Test

Implementation of a COVID-19 Test

CTS Tampa lab implemented the Ortho Clinical Diagnostics VITROS® testing platform to perform COVID-1...

Read More >
CTS implements licensesd Zika test

CTS implements licensesd Zika test

Transitioned all 6 CTS labs from an investigational new drug (IND) to a licensed Zika test, and anno...

Read More >

Operational Excellence

CTS embraces a company-wide operational excellence initiative designed to change the culture to enha...

Read More >

Research Consortium

CTS Research Consortium was established to further CTS’s leadership in infectious disease research....

Read More >
Source plasma partners

Source plasma partners

By the end of 2017, CTS has secured three source plasma partners and continues to seek additional pa...

Read More >